Back to Search
SARA GORE, M.D.
M.D.
Infectious Disease Physician
NPI: 1407234198IndividualAccepts Medicare
Specialties, Licenses & Credentials
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
DR.0064342(CO)
CMS Specialties
PrimaryINFECTIOUS DISEASE
Education
TULANE UNIVERSITY SCHOOL OF MEDICINE
Class of 2015
Research & Publications (20)
Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches.
PMID 18813208·Cancer Control·2008
6-review
Rappertk: a versatile engine for discrete restraint-based conformational sampling of macromolecules.
PMID 17376228·BMC Struct Biol·2007
8-other
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
PMID 16778214·Cancer Res·2006
8-other
Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
PMID 16403407·J Natl Compr Canc Netw·2006
6-review
Enrofloxacin pharmacokinetics in the European cuttlefish, Sepia officinalis, after a single i.v. injection and bath administration.
PMID 16207305·J Vet Pharmacol Ther·2005
7-preclinical
Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
PMID 16341238·Nat Clin Pract Oncol·2005
6-review
Inhibitors of signaling in myelodysplastic syndrome.
PMID 15494298·Best Pract Res Clin Haematol·2004
6-review
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
PMID 11948101·Clin Cancer Res·2002
3-trial
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
PMID 11489809·Clin Cancer Res·2001
3-trial
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.
PMID 11093362·Expert Opin Investig Drugs·2000
6-review
Design, synthesis and pharmacological screening of novel nitric oxide donors containing 1,5-diarylpyrazolin-3-one as nontoxic NSAIDs.
PMID 19647903·Eur J Med Chem·2009
7-preclinical
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
PMID 19546476·Blood·2009
3-trial
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
PMID 19230772·Lancet Oncol·2009
3-trial
Novel 4-(morpholin-4-yl)-N'-(arylidene)benzohydrazides: synthesis, antimycobacterial activity and QSAR investigations.
PMID 19464085·Eur J Med Chem·2009
8-other
Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation?
PMID 19479712·J Pathol·2009
8-other
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
PMID 19652201·Blood·2009
3-trial
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
PMID 19167676·Biol Blood Marrow Transplant·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1550 S POTOMAC ST STE 270
AURORA, CO 80012 - Phone
- (303) 750-1800
Quick Facts
- NPI
- 1407234198
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile